The online version of this article (doi:10.1186/1476-4598-11-89) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
IPM design the overall study, conducted the majority of experiments, collected and analyzed the data. CM, KN, TB, KW, HS contributed to experimental design. CM, ACC, PZ, HS conducted experiments. SAM offered reagents. AN guided the study. IPM and AN wrote the manuscript. All authors discussed the results and commented on the manuscript. All authors read and approved the final manuscript.
Transgenes introduced into cancer cell lines serve as powerful tools for identification of genes involved in cancer. However, the random nature of genomic integration site of a transgene highly influences the fidelity, reliability and level of its expression. In order to alleviate this bottleneck, we characterized the potential utility of a novel PhiC31 integrase-mediated site-specific insertion system (PhiC31-IMSI) for introduction of transgenes into a pre-inserted docking site in the genome of cancer cells.
According to this system, a “docking-site” was first randomly inserted into human cancer cell lines and clones with a single copy were selected. Subsequently, an “incoming” vector containing the gene of interest was specifically inserted in the docking-site using PhiC31.
Using the Pc-3 and SKOV-3 cancer cell lines, we showed that transgene insertion is reproducible and reliable. Furthermore, the selection system ensured that all surviving stable transgenic lines harbored the correct integration site. We demonstrated that the expression levels of reporter genes, such as green fluorescent protein and luciferase, from the same locus were comparable among sister, isogenic clones. Using in vivo xenograft studies, we showed that the genetically altered cancer cell lines retain the properties of the parental line. To achieve temporal control of transgene expression, we coupled our insertion strategy with the doxycycline inducible system and demonstrated tight regulation of the expression of the antiangiogenic molecule sFlt-1-Fc in Pc-3 cells. Furthermore, we introduced the luciferase gene into the insertion cassette allowing for possible live imaging of cancer cells in transplantation assays. We also generated a series of Gateway cloning-compatible intermediate cassettes ready for high-throughput cloning of transgenes and demonstrated that PhiC31-IMSI can be achieved in a high throughput 96-well plate format.
The novel PhiC31-IMSI system described in this study represents a powerful tool that can facilitate the characterization of cancer-related genes.
Additional file 1: Highly efficient site-specific transgenesis in cancer cell lines. (PDF 9 MB)12943_2012_1062_MOESM1_ESM.pdf
Authors’ original file for figure 112943_2012_1062_MOESM2_ESM.tiff
Authors’ original file for figure 212943_2012_1062_MOESM3_ESM.tiff
Authors’ original file for figure 312943_2012_1062_MOESM4_ESM.tiff
Authors’ original file for figure 412943_2012_1062_MOESM5_ESM.tiff
Authors’ original file for figure 512943_2012_1062_MOESM6_ESM.tiff
Cimoli G, Malacarne D, Ponassi R, Valenti M, Alberti S, Parodi S: Meta-analysis of the role of p53 status in isogenic systems tested for sensitivity to cytotoxic antineoplastic drugs. Biochim Biophys Acta. 2004, 1705 (2): 103-120. PubMed
Belteki G, Haigh J, Kabacs N, Haigh K, Sison K, Costantini F, Whitsett J, Quaggin SE, Nagy A: Conditional and inducible transgene expression in mice through the combinatorial use of Cre-mediated recombination and tetracycline induction. Nucleic Acids Res. 2005, 33 (5): e51- 10.1093/nar/gni051 PubMedCentralCrossRefPubMed
Bode J, Schlake T, Iber M, Schubeler D, Seibler J, Snezhkov E, Nikolaev L: The transgeneticist's toolbox: novel methods for the targeted modification of eukaryotic genomes. Biol Chem. 2000, 381 (9–10): 801-813. PubMed
Agha-Mohammadi S, O'Malley M, Etemad A, Wang Z, Xiao X, Lotze MT: Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness. J Gene Med. 2004, 6 (7): 817-828. 10.1002/jgm.566 CrossRefPubMed
Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W: Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci USA. 2000, 97 (14): 7963-7968. 10.1073/pnas.130192197 PubMedCentralCrossRefPubMed
Barleon B, Totzke F, Herzog C, Blanke S, Kremmer E, Siemeister G, Marmé D, Martiny-Baron G: Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J Biol Chem. 1997, 272 (16): 10382-10388. 10.1074/jbc.272.16.10382 CrossRefPubMed
Schubeler D, Lorincz MC, Cimbora DM, Telling A, Feng YQ, Bouhassira EE, Groudine M: Genomic targeting of methylated DNA: influence of methylation on transcription, replication, chromatin structure, and histone acetylation. Mol Cell Biol. 2000, 20 (24): 9103-9112. 10.1128/MCB.20.24.9103-9112.2000 PubMedCentralCrossRefPubMed
- Highly efficient site-specific transgenesis in cancer cell lines
Iacovos P Michael
Anthony C Chiu
- BioMed Central
Neu im Fachgebiet Onkologie
e.Med Kampagnen-Visual, Mail Icon II